COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research from NIH: https://www.nih.gov/coronavirus.

Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/.

FULL TEXT LINKS

Clinical Trial > Ann Emerg Med. 2002 Jun;39(6):585-91. doi: 10.1067/mem.2002.123300.

## A Randomized Clinical Trial of Nebulized Magnesium Sulfate in Addition to Albuterol in the Treatment of Acute Mild-To-Moderate Asthma Exacerbations in **Adults**

Olga Bessmertny <sup>1</sup>, Robert V DiGregorio, Henry Cohen, Ellen Becker, Darrell Looney, Jonathan Golden, Lewis Kohl, Thomas Johnson

Affiliations

## Affiliation

1 Long Island University, Arnold and Marie Schwartz College of Pharmacy, Brookdale University Hospital and Medical Center, Brooklyn, NY 11212-3198, USA.

PMID: 12023699 DOI: 10.1067/mem 2002.123300

## **Abstract**

Study objective: We sought to compare the efficacy and safety of nebulized magnesium sulfate (MgSO(4)) plus albuterol with that of albuterol alone in adult patients with mild-to-moderate acute asthma exacerbations.

Methods: Patients were randomized to receive nebulized MgSO(4) (384 mg in 6 mL of sterile water) or an equal volume of placebo (normal saline solution) in a double-blind fashion after each dose of nebulized albuterol administered (2.5 mg/3 mL) every 20 minutes for the first hour of the study. Spirometry was performed at baseline and every 20 minutes for 2 hours. Monitoring for safety included vital signs, pulse oximetry, and serum magnesium levels. Improvement in percent predicted forced expiratory volume in 1 second was chosen as a primary efficacy end point.

Results: Among 74 patients enrolled, 37 were randomized to each of 2 study groups. There were no statistically or clinically significant differences between the 2 study groups in percent predicted forced expiratory volume in 1 second at any point during the trial or overall. There were no significant differences in vital signs, pulse oximetry, or serum magnesium levels at any point during the study.

Conclusion: The combination of nebulized MgSO(4) and albuterol provides no benefit in addition to that provided by therapy with albuterol in adult patients with mild-to-moderate asthma exacerbations. The efficacy of nebulized MgSO(4) in patients with severe asthma exacerbations remains unknown.

## LinkOut - more resources

**Full Text Sources** 

Ovid Technologies, Inc.

Medical

Genetic Alliance

**Elsevier Science** 

MedlinePlus Health Information

Miscellaneous

Hazardous Substances Data Bank